1[1]Mountain CF.Revisions in the international system for staging lung cancer[J]. Chest,1997,111:1710.
2[2]Choy H,Chakravarthy A,Devore RF,et al.Weekly irinotecan and concurrent radiation therapy for stage Ⅲ unresectable NSCLC[J].Oncology (Huntingt) 2000, 14: 43.
3[3]Masters GA, Vokes EE. Radiotherapy and concomitant chemotherapy in Bertino J(ed): Encyclopedia of Cancer[M].San Diego,CA, Academic, 1997. 1471.
4[4]Blanke C, DeVore R, Shyr Y,et al. A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage Ⅲ nonsmall cell lung cancer[J].lnt J Radiat Oncol Biol Phys, 1997, 37: 111.
5[5]Lau D, Leigh B, Gandara D, et al. Twiceweekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage Ⅲnon-small-cell lung cancer: a California Cancer Consortium phase Ⅱ trial[J]. J Clin Oncol, 2001, 19: 442.
6[6]Yokoyama A, Kurita Y, Saijo N, et al. Dosefinding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage Ⅲnon-small lung cancer[J].Br J Cancer, 1998, 78: 257.
7[7]Baldini E, Silvano G, Tibaldi C, et al. Sequential chemoradiation therapy with vinorelbine, ifosfamide, cisplatin in stage ⅢB nn-small cell lung cancer:a phase Ⅱstudy[J].Semin Oncol, 2000, 27: 28.
8[8]Comella G, Frasci G, Scoppa G, et al. Weekly paclitaxel/cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer:a phase I study[J]. Semin Oncol, 1997, 24: S12.
9[9]Komaki R, Scott C, Lee JS, et al. Impact of adding concurrent chemotherapy to hyperfrationated radiotherapy for locally advanced non-small cell lung cancer(NSCLC):comparison of RTOG 83-11and RTOG 91-06[J].Am J Clin Oncol, 1997, 20: 435.
10[10]Lee JS, Komaki R, Fosseler FV, et al. A pilot trial of hyperfractionated thoracic radition therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer:a 5-year follow-up report[J].lnt J Radiat Oncol Biol Phys, 1998, 42: 479.
2Borgne A, Versteege I, Mahe M, et al. Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment[ J]. Oncogene, 2006, 25 (56) : 7361 - 7372.
3Li J P, Yang J L. Cyclin B1 proteolysis via p38 MAPK signaling participates in G2 checkpoint elicited by arsenite [ J ]. J Cell Physiol, 2007, 212(2) : 481 -488.
4Wolgemuth D J. Function of cyclins in regulating the mitotic and meiotic cell cycles in male germ cells [ J ]. Cell Cycle, 2008, 7 ( 22 ) : 3509 - 3513.
5Zhao M, Kim Y T, Yoon B S, et al. Expression profiling of cyclin B1 and D1 in cervical carcinoma[J]. Exp Oncol, 2006, 28 (1) : 44 -48.
6Song Y, Zhao C, Dong L, et al. Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis [ J ]. Carcinogenesis, 2008, 29 (2) : 307 - 315.
7Takita M, Furuya T, Sugita T, et al. An analysis of changes in the expression of cyclins A and B1 by the cell array system during the cell cycle : comparison between cell synchronization methods [ J ]. Cytometry A, 2003, 55(1): 24-29.
8Wasner M, Haugwitz U, Reinhard W, et al. Three CCAAT-boxes and a single cell cycle genes homology region (CHR) are the major regulating sites for transcription from the human cyclin B2 promoter [J]. Gene, 2003, 312:225-237.
9Hwang A, Maity A, McKenna W G, et al. Cell cycle-dependent regulation of the cyclin B1 promoter [J].J Biol Chem, 1995,270 (47) : 28419 - 28424.
10Borgne A,Versteege I,Mahe M,et al.Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment[J].Oncogene,2006,25(5):7361.
